Trial Profile
Evaluation of Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron / Rebetol in Conjunction With a Patient Assistance Program - Non Interventional Observational Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2b/ribavirin (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms COMPLETED
- Sponsors Merck Sharp & Dohme Corp.
- 21 Aug 2009 Primary outcome amended as reported by ClinicalTrials.gov.
- 23 Aug 2008 New trial record.